SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

对SGLT2抑制剂的关注并不仅限于其降糖功效，研究人员在对糖尿病患者进行临床研究时发现，服用此类药物的患者不仅血糖得到控制，尿酸水平也出现了意外的下降，痛风发作的次数也明显减少。对此，科学家们开始深入探讨SGLT2抑制剂与痛风之间的潜在关系。

The following is a summary of “Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: Insights from the CREDENCE trial,” published in the February 2025 issue of Nephrology Dialysis ...

回望过去，细数SGLT2抑制剂跨越百年的成长历史1835年早在1835年，法国科学家克里斯托夫·彼得森首次从苹果树的根皮中分离出一种黄酮类化合物，命名为根皮苷（phlorizin），这是已知的第一个具有SGLT抑制活性的天然产物[1,2]。1886年 ...

Mankind Pharma and other domestic companies have launched generic versions of the popular diabetes drug Empagliflozin at ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

The pharmacokinetics of this compound are similar in study subjects with diabetes and in those without. Age, gender, body weight, race, administration with food, or mild renal impairment do not ...

SGLT2 inhibitors are a new family of agents ... are genital mycotic and urinary tract infections. Dapagliflozin and canagliflozin are the first agents of this class, approved from the European ...

Lexicon Pharmaceuticals has reported that LX4211, an inhibitor of the sodium-dependent glucose transporter 2 (SGLT2; also known as SLC5A2), significantly improved glycaemic control in a Phase II ...

Although low-dose dapagliflozin was less effective in preventing hospitalization for heart failure, SGLT-2 inhibitors had similar cardiovascular outcomes in T2D. Canagliflozin and dapagliflozin ...

In 2020, the FDA issued guidance that patients taking an SGLT2 inhibitor -- including canagliflozin (Invokana), dapagliflozin (Farxiga), empagliflozin (Jardiance), ertugliflozin (Steglatro), and ...